Varicella-Zoster Virus (VZV) Antibody, IgM, Serum
Use
Varicella-zoster virus (VZV), a herpes virus, causes two distinct exanthematous diseases: chickenpox and herpes zoster (shingles). Diagnosing the acute-phase infection with VZV is important, especially in high-risk populations. These include pregnant women, immunocompromised patients, and hospital personnel who may spread the infection. While the clinical presentation is usually characteristic, serologic evaluation is needed for atypical or systemic infections, especially in hospital settings, to prevent nosocomial infections which can be life-threatening to immunocompromised patients.
Special Instructions
Not provided.
Limitations
This test's performance characteristics in vaccinated individuals have not been established. It must be performed on serum. The use of whole blood, plasma, or cord blood is not validated. Positive results from cord blood or neonates should be interpreted with caution. Results from immunocompromised patients should also be interpreted carefully.
FDA ApprovedNew York Approved
Methodology
Immunoassay (IFA)
Biomarkers
Varicella-Zoster Virus (VZV) IgM
Antibody
LOINC Codes
- 43588-3 - VZV IgM Ser Ql IF
- 43588-3 - VZV IgM Ser Ql IF
Result Turnaround Time
1-3 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
0.5 mL
Minimum Volume
0.2 mL
Container
Plastic vial
Collection Instructions
Centrifuge and aliquot serum into a plastic vial.
Causes for Rejection
Gross hemolysis, gross lipemia, gross icterus, heat-inactivated specimen
Stability Requirements
| Temperature | Period |
|---|---|
| Refrigerated | 14 days |
| Frozen | 14 days |